CY1113415T1 - Υποκατασταθεντα ν-φαινυλμεθυλ-5-οξο-προλιν-2-αμιδια ως ανταγωνιστες υποδοχεα ρ2χ7 και οι μεθοδοι χρησεως τους - Google Patents
Υποκατασταθεντα ν-φαινυλμεθυλ-5-οξο-προλιν-2-αμιδια ως ανταγωνιστες υποδοχεα ρ2χ7 και οι μεθοδοι χρησεως τουςInfo
- Publication number
- CY1113415T1 CY1113415T1 CY20121100671T CY121100671T CY1113415T1 CY 1113415 T1 CY1113415 T1 CY 1113415T1 CY 20121100671 T CY20121100671 T CY 20121100671T CY 121100671 T CY121100671 T CY 121100671T CY 1113415 T1 CY1113415 T1 CY 1113415T1
- Authority
- CY
- Cyprus
- Prior art keywords
- oxo
- phenylmethyl
- proline
- amides
- substituted
- Prior art date
Links
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 4
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 4
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- HWHWCOBKVKZESC-BYPYZUCNSA-N (2s)-3-oxopyrrolidine-2-carboxamide Chemical class NC(=O)[C@H]1NCCC1=O HWHWCOBKVKZESC-BYPYZUCNSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0613473A GB0613473D0 (en) | 2006-07-06 | 2006-07-06 | Novel compounds |
| GB0622825A GB0622825D0 (en) | 2006-11-15 | 2006-11-15 | Novel compounds |
| GB0705263A GB0705263D0 (en) | 2007-03-19 | 2007-03-19 | Novel compounds |
| GB0711439A GB0711439D0 (en) | 2007-06-13 | 2007-06-13 | Novel receptor antagonists and their methods of use |
| EP07787001A EP2049478B1 (en) | 2006-07-06 | 2007-07-03 | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113415T1 true CY1113415T1 (el) | 2016-06-22 |
Family
ID=38508907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100671T CY1113415T1 (el) | 2006-07-06 | 2012-07-26 | Υποκατασταθεντα ν-φαινυλμεθυλ-5-οξο-προλιν-2-αμιδια ως ανταγωνιστες υποδοχεα ρ2χ7 και οι μεθοδοι χρησεως τους |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7718693B2 (enExample) |
| EP (1) | EP2049478B1 (enExample) |
| JP (1) | JP5283620B2 (enExample) |
| KR (2) | KR101398264B1 (enExample) |
| AR (1) | AR061815A1 (enExample) |
| AU (1) | AU2007271182B2 (enExample) |
| BR (1) | BRPI0714062A2 (enExample) |
| CA (1) | CA2655675A1 (enExample) |
| CR (2) | CR10545A (enExample) |
| CY (1) | CY1113415T1 (enExample) |
| DK (1) | DK2049478T3 (enExample) |
| EA (1) | EA016076B1 (enExample) |
| ES (1) | ES2385505T3 (enExample) |
| HR (1) | HRP20120505T1 (enExample) |
| IL (1) | IL196181A0 (enExample) |
| MA (1) | MA30607B1 (enExample) |
| MX (1) | MX2009000117A (enExample) |
| NO (1) | NO20090267L (enExample) |
| PE (1) | PE20080997A1 (enExample) |
| PL (1) | PL2049478T3 (enExample) |
| PT (1) | PT2049478E (enExample) |
| SI (1) | SI2049478T1 (enExample) |
| TW (1) | TW200819127A (enExample) |
| UA (1) | UA100227C2 (enExample) |
| WO (1) | WO2008003697A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| ATE532789T1 (de) | 2006-07-06 | 2011-11-15 | Array Biopharma Inc | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| NZ573979A (en) | 2006-07-06 | 2012-02-24 | Array Biopharma Inc | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| CA2655675A1 (en) | 2006-07-06 | 2008-01-10 | Glaxo Group Limited | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| DE102006047619B4 (de) * | 2006-10-09 | 2008-11-13 | Clariant International Limited | Verfahren zur Herstellung basischer Fettsäureamide |
| DE102006047617B4 (de) * | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
| EP3034046B1 (en) * | 2006-10-22 | 2018-01-17 | IDEV Technologies, INC. | Methods for securing strand ends and the resulting devices |
| GB0705882D0 (en) * | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
| WO2008116845A1 (en) * | 2007-03-28 | 2008-10-02 | Glaxo Group Limited | Piperidinone carboxamide derivatives as p2x7 modulators |
| JP2010522710A (ja) * | 2007-03-29 | 2010-07-08 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体 |
| JP2010523524A (ja) * | 2007-04-03 | 2010-07-15 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのイミダゾリジンカルボキサミド誘導体 |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| MX2009014013A (es) | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| ES2551352T3 (es) | 2007-07-05 | 2015-11-18 | Array Biopharma, Inc. | Pirimido ciclopentanos útiles para el tratamiento de enfermedades inflamatorias o hiperproliferativas |
| WO2009074518A1 (en) * | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations of prolinamide p2x7 modulators with further therapeutic agents |
| GB0724625D0 (en) * | 2007-12-18 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
| KR20100099178A (ko) * | 2007-12-18 | 2010-09-10 | 글락소 그룹 리미티드 | Ｐ2ｘ7 조절제로서의 5-옥소-3-피롤리딘카르복스아미드 유도체 |
| ES2422733T3 (es) | 2008-01-09 | 2013-09-13 | Array Biopharma Inc | Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT |
| EP2240455B1 (en) | 2008-01-09 | 2012-12-26 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| GB0803729D0 (en) * | 2008-02-29 | 2008-04-09 | Ge Healthcare Ltd | Imaging the central nervous system |
| ES2357682T3 (es) | 2008-03-25 | 2011-04-28 | Affectis Pharmaceuticals Ag | Antagonistas de p2x7r novedosos y su utilización. |
| DE102008017214B4 (de) * | 2008-04-04 | 2012-02-16 | Clariant International Limited | Kontinuierliches Verfahren zur Herstellung von Fettsäurealkanolamiden |
| DE102008017217A1 (de) * | 2008-04-04 | 2009-10-08 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden aromatischer Carbonsäuren |
| DE102008017213B4 (de) * | 2008-04-04 | 2012-08-09 | Clariant International Limited | Kontinuierliches Verfahren zur Herstellung von Amiden aliphatischer Hydroxycarbonsäuren |
| DE102008017219A1 (de) * | 2008-04-04 | 2009-10-08 | Clariant International Ltd. | Verfahren zur Herstellung von Amiden in Gegenwart von überhitztem Wasser |
| DE102008017218B4 (de) * | 2008-04-04 | 2011-09-22 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden niederer aliphatischer Carbonsäuren |
| DE102008017215B4 (de) * | 2008-04-04 | 2012-08-09 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren |
| DE102008017216B4 (de) * | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
| US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
| CN102395562A (zh) | 2009-04-14 | 2012-03-28 | 阿费克蒂斯制药股份公司 | 新的p2x7r拮抗剂及其用途 |
| DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
| DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
| DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
| US8691556B2 (en) * | 2009-12-08 | 2014-04-08 | Vanderbilt University | Methods and compositions for vein harvest and autografting |
| JP2013521002A (ja) | 2010-03-05 | 2013-06-10 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 誘導樹状細胞組成物及びその使用 |
| EP2386541A1 (en) | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
| DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
| DE102010056564A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Limited | Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung |
| CN103402996B (zh) * | 2011-01-04 | 2015-02-11 | 诺瓦提斯公司 | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| EP3009427B1 (en) * | 2011-03-03 | 2019-12-18 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| SG10201504303SA (en) | 2011-04-01 | 2015-07-30 | Genentech Inc | Combinations Of AKT Inhibitor Compounds And Chemotherapeutic Agents, And Methods Of Use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2013014587A1 (en) | 2011-07-22 | 2013-01-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| TWI576347B (zh) | 2012-01-20 | 2017-04-01 | 艾克泰聯製藥有限公司 | 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物 |
| US9075975B2 (en) * | 2012-02-21 | 2015-07-07 | Andrew Bud | Online pseudonym verification and identity validation |
| PL2931717T3 (pl) | 2012-12-12 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Pochodne indolokarboksyamidu jako antagoniści receptora p2x7 |
| CN104854087B (zh) | 2012-12-18 | 2017-03-22 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物 |
| CN104918617B (zh) | 2013-01-22 | 2017-05-10 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
| WO2014115078A1 (en) | 2013-01-22 | 2014-07-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| FR3026102A1 (fr) * | 2014-09-19 | 2016-03-25 | Univ Nice Sophia Antipolis | Conjugues d'acide amine-pyridine/pyridinium et leurs utilisations en tant qu'agents biocides |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| HUE049918T2 (hu) | 2016-05-31 | 2020-11-30 | Kalvista Pharmaceuticals Ltd | Pirazol-származékok mint plazma kallikrein inhibitorok |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| DE102016111711A1 (de) * | 2016-06-27 | 2017-12-28 | Abb Schweiz Ag | Installationsschaltgerät mit einem Gehäuse und mit einer Schraubanschlussklemme |
| RU2724350C1 (ru) * | 2017-03-13 | 2020-06-23 | Раквалиа Фарма Инк. | Производные тетрагидрохинолина в качестве антагонистов рецептора р2х7 |
| US20200123104A1 (en) * | 2017-06-28 | 2020-04-23 | Indiana University Research And Technology Corporation | Pharmaceutical agent that binds the p2x7 receptor |
| LT3716952T (lt) | 2017-11-29 | 2022-04-11 | Kalvista Pharmaceuticals Limited | Vaisto formos, apimančios plazmos kalikreino inhibitorių |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| US11919854B2 (en) | 2018-03-29 | 2024-03-05 | Centre National De La Recherche Scientifique | P2RX7 modulators in therapy |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| PL4125843T3 (pl) | 2020-03-31 | 2025-09-22 | Remicine IP B.V. | Leczenie ciężkiego zespołu zapalnego |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2651639A (en) * | 1951-08-22 | 1953-09-08 | American Cyanamid Co | 2-pyrrolidone-5-carboxamide derivatives and methods of preparing the same |
| FR2273533A1 (fr) * | 1974-06-04 | 1976-01-02 | Ferlux Sa | Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5 |
| JPH0699307B2 (ja) * | 1987-08-20 | 1994-12-07 | キッセイ薬品工業株式会社 | 抗痴呆剤 |
| US4772601A (en) | 1988-01-25 | 1988-09-20 | Hoechst-Roussel Pharmaceuticals, Inc. | 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use |
| WO1997017958A1 (en) | 1995-11-13 | 1997-05-22 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| US6054579A (en) * | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
| SE9704546D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| AU2160900A (en) * | 1998-12-11 | 2000-06-26 | American Biogenetic Sciences, Inc. | Substituted nitrogen heterocyclic compounds and therapeutic uses thereof |
| CN1215028C (zh) | 2002-05-24 | 2005-08-17 | 中国科学院上海有机化学研究所 | 外消旋的联二酚的光学拆分方法 |
| US7288538B2 (en) * | 2003-02-20 | 2007-10-30 | Encysive Pharmaceuticals, Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
| SI1663185T1 (sl) * | 2003-09-22 | 2009-04-30 | Onepharm Res & Dev Gmbh | Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti |
| WO2007115403A1 (en) * | 2006-04-10 | 2007-10-18 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| US20080076924A1 (en) * | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
| CA2655675A1 (en) * | 2006-07-06 | 2008-01-10 | Glaxo Group Limited | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| EP2046740B1 (en) * | 2006-07-22 | 2012-05-23 | Oxagen Limited | Compounds having crth2 antagonist activity |
| EA201300152A1 (ru) * | 2006-11-27 | 2013-07-30 | Х. Лундбекк А/С | Гетероариламидные производные |
| ES2576643T3 (es) * | 2007-03-09 | 2016-07-08 | Second Genome, Inc. | Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos |
| GB0705882D0 (en) * | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
| WO2008116845A1 (en) * | 2007-03-28 | 2008-10-02 | Glaxo Group Limited | Piperidinone carboxamide derivatives as p2x7 modulators |
| JP2010522710A (ja) * | 2007-03-29 | 2010-07-08 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体 |
| JP2010523524A (ja) * | 2007-04-03 | 2010-07-15 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのイミダゾリジンカルボキサミド誘導体 |
| EP2155744A1 (en) * | 2007-04-10 | 2010-02-24 | Lundbeck, H., A/S | Heteroaryl amide analogues as p2x7 antagonists |
-
2007
- 2007-07-03 CA CA002655675A patent/CA2655675A1/en not_active Abandoned
- 2007-07-03 PT PT07787001T patent/PT2049478E/pt unknown
- 2007-07-03 PL PL07787001T patent/PL2049478T3/pl unknown
- 2007-07-03 DK DK07787001.2T patent/DK2049478T3/da active
- 2007-07-03 HR HRP20120505TT patent/HRP20120505T1/hr unknown
- 2007-07-03 BR BRPI0714062-2A patent/BRPI0714062A2/pt not_active IP Right Cessation
- 2007-07-03 WO PCT/EP2007/056675 patent/WO2008003697A1/en not_active Ceased
- 2007-07-03 EP EP07787001A patent/EP2049478B1/en active Active
- 2007-07-03 SI SI200730962T patent/SI2049478T1/sl unknown
- 2007-07-03 UA UAA200900103A patent/UA100227C2/uk unknown
- 2007-07-03 ES ES07787001T patent/ES2385505T3/es active Active
- 2007-07-03 KR KR1020097002352A patent/KR101398264B1/ko not_active Expired - Fee Related
- 2007-07-03 JP JP2009517252A patent/JP5283620B2/ja not_active Expired - Fee Related
- 2007-07-03 KR KR1020147001116A patent/KR20140016431A/ko not_active Ceased
- 2007-07-03 US US11/772,977 patent/US7718693B2/en not_active Expired - Fee Related
- 2007-07-03 EA EA200970085A patent/EA016076B1/ru not_active IP Right Cessation
- 2007-07-03 MX MX2009000117A patent/MX2009000117A/es active IP Right Grant
- 2007-07-03 AU AU2007271182A patent/AU2007271182B2/en not_active Ceased
- 2007-07-04 TW TW096124227A patent/TW200819127A/zh unknown
- 2007-07-04 PE PE2007000855A patent/PE20080997A1/es not_active Application Discontinuation
- 2007-07-04 AR ARP070102985A patent/AR061815A1/es unknown
-
2008
- 2008-12-19 CR CR10545A patent/CR10545A/es unknown
- 2008-12-25 IL IL196181A patent/IL196181A0/en unknown
-
2009
- 2009-01-16 NO NO20090267A patent/NO20090267L/no not_active Application Discontinuation
- 2009-01-30 MA MA31599A patent/MA30607B1/fr unknown
-
2010
- 2010-02-18 US US12/708,077 patent/US8048907B2/en not_active Expired - Fee Related
-
2012
- 2012-07-26 CY CY20121100671T patent/CY1113415T1/el unknown
-
2014
- 2014-11-10 CR CR20140515A patent/CR20140515A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113415T1 (el) | Υποκατασταθεντα ν-φαινυλμεθυλ-5-οξο-προλιν-2-αμιδια ως ανταγωνιστες υποδοχεα ρ2χ7 και οι μεθοδοι χρησεως τους | |
| CY1114092T1 (el) | Σπειρο υποκατεστημενες ενωσεις ως αναστολεις αγγειογενεσης | |
| CY1110190T1 (el) | Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38 | |
| BRPI0605921B8 (pt) | compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
| CY1111927T1 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
| EA201171081A1 (ru) | Производные индола в качестве антагонистов рецептора crth2 | |
| CY1118416T1 (el) | Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα | |
| CY1110977T1 (el) | Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου | |
| CY1111903T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση | |
| CY1117319T1 (el) | Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης | |
| CY1111603T1 (el) | Παραγωγα benzimidazole και η χρηση τους για την τροποποιηση της συνθεσης ληπτη gabaa | |
| CY1113642T1 (el) | Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl | |
| CY1114539T1 (el) | Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων | |
| BRPI0818672A2 (pt) | 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| CY1111469T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ 3-ΦΑΙΝΥΛΘΕΙΟ-1Η-ΙΝΔΟΛΗ-1-ΟΞΙΚΟΥ ΟΞΕΟΣ ΩΣ ΡΥΘΜΙΣΤΕΣ ΤΗΣ ΔΡΑΣΗΣ ΤΟΥ ΥΠΟΔΟΧΕΑ CRTh2 | |
| DE602007013440D1 (de) | Substituierte indole | |
| CY1110583T1 (el) | Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων | |
| CL2009001274A1 (es) | Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer. | |
| CY1110854T1 (el) | Πυραζολοπυριμιδινες θειαζολιου ως ανταγωνιστες υποδοχεων crf1 | |
| CY1111977T1 (el) | Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
| CY1112095T1 (el) | Υποκατεστημενα σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
| EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
| EA201070804A1 (ru) | (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения |